Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.43 |
| ▸ | PDE4A | P27815 | 9/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylleucine SCHEMBL20474775 | 0.94 | LMNA (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Levacetylleucine SCHEMBL21229236 | 0.94 | LMNA (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Levacetylleucine SCHEMBL756572 | 0.94 | LMNA (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Levacetylleucine SCHEMBL302605 | 0.94 | LMNA (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Levacetylleucine SCHEMBL7084218 | 0.94 | LMNA (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Levacetylleucine SCHEMBL704275 | 0.91 | FOLH1 (0.38) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Levacetylleucine SCHEMBL703860 | 0.87 | FOLH1 (0.42) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL10029180 | 0.83 | PDE4B (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL706429 | 0.83 | PDE4B (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Leucine SCHEMBL18074074 | 0.81 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264524-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9296689-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-8404737-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120252864-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2012-10-04 | — | — | US | disclosed |
| US-8124646-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252864-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | PDE4B 67/4885PDE4C 108/4885PDE4A 42/4885 |
| US-20160264524-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | PDE4B 67/4885PDE4C 108/4885PDE4A 42/4885 |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | PDE4B 67/4885PDE4C 108/4885PDE4A 42/4885 |
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | PDE4B 67/4885PDE4C 108/4885PDE4A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.